Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2007
12/21/2007CA2653757A1 Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
12/21/2007CA2653686A1 Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
12/21/2007CA2653682A1 Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
12/21/2007CA2653679A1 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
12/21/2007CA2653654A1 Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
12/21/2007CA2653650A1 Heterocyclic aspartyl protease inhibitors
12/21/2007CA2653646A1 Oxime derivatives as inhibitors of macrophage migration inhibitory factor
12/21/2007CA2653550A1 Crystalline form of (trans-4- [( { 5-[(3,4-difluorophenyl) amino]-1,3,4-oxadiazol-2-yl}carbonyl)amino]phenyl}cyclohexyl) acetic acid
12/21/2007CA2653524A1 Pyrrolidine derivatives useful against diseases that depends on activity of renin
12/21/2007CA2653047A1 Type-2 diabetes combination wafer
12/21/2007CA2653030A1 Ache-nmda combination wafer
12/21/2007CA2652669A1 Benzazepinones as sodium channel blockers
12/21/2007CA2652524A1 Novel mch receptor antagonists
12/21/2007CA2652516A1 Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
12/21/2007CA2652515A1 Opioid combination wafer
12/21/2007CA2652476A1 Combination antidepressants wafer
12/21/2007CA2652385A1 Novel mch receptor antagonists
12/21/2007CA2652256A1 Indenoisoquinoline-releasable polymer conjugates
12/21/2007CA2652133A1 Method for treating renal disease
12/21/2007CA2651684A1 Peptide compounds for treating refractory status epilepticus
12/21/2007CA2651679A1 Pharmaceutical composition with synergistic anticonvulsant effect
12/21/2007CA2650666A1 Substituted cyanopyridines as protein kinase inhibitors
12/21/2007CA2650263A1 Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
12/21/2007CA2649877A1 Gemcitabine combination therapy
12/21/2007CA2649576A1 Method for enhancing cognitive function
12/21/2007CA2649361A1 Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
12/21/2007CA2647990A1 New chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof
12/21/2007CA2626273A1 Cefquinome compositions and methods of their use
12/21/2007CA2550753A1 Liquid vitamin and supplement formulations
12/20/2007US20070294107 Uses Of Endopeptidases In Treatment Of Disease
12/20/2007US20070293703 Preparation and purification of synthetic capsaicin
12/20/2007US20070293698 Compositions of Allosteric Hemoglobin Modifiers and Methods of Making the Same
12/20/2007US20070293683 N-phenyl-2-pyrimidine-amine derivatives
12/20/2007US20070293674 Novel Saperconazole Crystalline Forms and Related Processes, Pharmaceutical Compositions and Methods
12/20/2007US20070293673 N-phenyl-2-pyrimidine-amine derivatives
12/20/2007US20070293672 N-phenyl-2-pyrimidine-amine derivatives
12/20/2007US20070293668 Phenylindoles for the treatment of HIV
12/20/2007US20070293587 Combating sinus, throat, and blood infections with xylitol delivered in the mouth
12/20/2007US20070293586 Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof
12/20/2007US20070293585 Gossypol co-crytals and the use thereof
12/20/2007US20070293584 Modified release formulations of a bupropion salt
12/20/2007US20070293583 Use of low-dose ladostigil for neuroprotection
12/20/2007US20070293582 Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
12/20/2007US20070293581 Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies
12/20/2007US20070293580 Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies
12/20/2007US20070293579 Use of carp inhibitors for the treatment of heart diseases
12/20/2007US20070293578 N1-(1-cyanocyclopropyl)-N2-(1-{4'-[2,2-difluoro-1-hydroxyethyl]biphenyl-4-yl}-2,2,2-trifluorethyl)-4-fluoro-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders
12/20/2007US20070293577 topical cosmetics such as Hydroxycitric acid-2-palmitate sodium salt, possessing body firming and slimming effects
12/20/2007US20070293576 Pharmaceutical Methods, Dosing Regimes And Dosage Forms For The Treatment Of Alzheimer's Disease
12/20/2007US20070293575 Compounds and methods for treatment of cancer-related anemia
12/20/2007US20070293574 Cholecystokinin-1(cck1) receptor antagonists in the treatment of gastrointestinal and related disorders
12/20/2007US20070293573 Glu2 receptor modulators
12/20/2007US20070293572 Anti-Fatigue Composition
12/20/2007US20070293571 Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
12/20/2007US20070293570 Pharmaceutical uses for alpha2delta ligands
12/20/2007US20070293569 Pentaerythritol Derivatives and a Method for Preparation Thereof, and Liquid Crystal Base Containing the Same
12/20/2007US20070293568 Neurocyte Protective Agent
12/20/2007US20070293567 Substituted biphenyl carboxylic acids and derivatives thereof
12/20/2007US20070293566 Combinations of vanadium with antidiabetics for glucose metabolism disorders
12/20/2007US20070293564 Dimeric compounds and their use as anti-viral agents
12/20/2007US20070293563 Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission
12/20/2007US20070293562 Antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
12/20/2007US20070293561 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists
12/20/2007US20070293560 Compounds and compositions
12/20/2007US20070293559 Orally Administered Agent For Preventing Or Improving Dry Station Of Skin
12/20/2007US20070293558 Ophthalmic Compositions for Treating Ocular Hypertension
12/20/2007US20070293557 Anticancer compositions, and methods of making and using the same
12/20/2007US20070293556 Prophylactic or Therapeutic Agent for Diabetic Maculopathy
12/20/2007US20070293555 4-methoxy-benzoic acid 1-imidazol-1-yl methyl-2-(4-fluorophenoxy)-ethyl ester; N-[(1-imidazol-1-yl methyl)-2-phenoxy-ethyl]-4-iodo-benzamide; cancer, inflammation, septic shock, infertility, preterm labor, pain, or an ischemia
12/20/2007US20070293554 Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
12/20/2007US20070293553 Diphenylurea Derivatives Useful As Potassium Channel Activators
12/20/2007US20070293552 Antihypertensive therapy method
12/20/2007US20070293551 Substituted gamma lactams as therapeutic agents
12/20/2007US20070293548 Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
12/20/2007US20070293547 Compounds and Compositions as Lxr Modulators
12/20/2007US20070293546 Preparation of rosiglitazone and its salts
12/20/2007US20070293545 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
12/20/2007US20070293544 Novel 4-Arylamino Pyridone Derivatives as Mek Inhibitors for the Treatment of Hyper-Proliferative Disorders
12/20/2007US20070293543 THRESHOLD BLOOD OMEPRAZOLE CONCENTRATION IS 50 NG/ML FOR THE MAINTENANCE OF INTRAGASTRIC pH OF AT LEAST 4.0 AFTER ORAL DOSING WITH CMA-OMEPRAZOLE, AGN 201904-Z
12/20/2007US20070293542 Selective Cox-2 Inhibitors
12/20/2007US20070293541 CB1 cannabinoid receptor antagonists; e.g. 5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-1H-pyrazole-3-carboxamide; various psychological, neurodegenerative, pain and cardiovascular disorders
12/20/2007US20070293540 for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition
12/20/2007US20070293539 Methods for the treatment of synucleinopathies
12/20/2007US20070293538 Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
12/20/2007US20070293537 Stable laquinimod preparations
12/20/2007US20070293536 Salts and polymorphs of a potent antidiabetic compound
12/20/2007US20070293535 Nuclear Transfer Promoter for Ddc42 Protein and Method of Screening the Dame
12/20/2007US20070293534 Process for the preparation of mivacurium chloride
12/20/2007US20070293533 SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
12/20/2007US20070293532 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use
12/20/2007US20070293531 Muscarinic Acetycholine Receptor Antagonists
12/20/2007US20070293530 Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
12/20/2007US20070293529 Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
12/20/2007US20070293528 non-steroidal partial activators and/or tissue-specific activators or inhibtors for androgen receptors, used for treating acne, alopecia, hirsutism, prostatic hyperplasia or prostate cancer
12/20/2007US20070293527 1-Methyl-1,3,4,5,6,11b-hexahydro-2H-11-oxa-4a-aza-benzo[a]fluoren-1-ol; alpha 2C adrergic receptors; adrenergic blocking agents; central nervous system; cognition activators; antidepressants; anxiolytic agents; peripheral nervous syster; antidiabetic agents; hypertensive agents; Raynaud's disease
12/20/2007US20070293526 Arylsulfonyl naphthalene derivatives and uses thereof
12/20/2007US20070293525 2-anilino-4-aminoalkyleneaminopyrimidines
12/20/2007US20070293524 Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade
12/20/2007US20070293523 inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents
12/20/2007US20070293522 2,4-pyrimidinediamine compounds and their uses
1 ... 3452 3453 3454 3455 3456 3457 3458 3459 3460 3461 3462 3463 3464 3465 3466 3467 3468 3469 3470 3471 3472 ... 7860